Docket No.: 05432/0204244-US0 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Thomas I fb. Cremers, Mr. et al.

Application No.: 10/596.348 Confirmation No.: 5528

Filed: June 9, 2006 Art Unit: N/A

For: THE COMBINATION OF A SEROTONIN Examiner: Not Yet Assigned REUPTAKE INHIBITOR AND A

HISTAMINE 3 RECEPTOR ANTAGONIST, INVERSE AGONIST OR PARTIAL AGONIST

AGONIST

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related ambitation.

 This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed: (Check one of the boxes A-D)

x A.	within three months of the filing date of the above-identified national application of within three months of the entry into the national stage of the above identified national application
B.	before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
C.	after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "i" below.
(check one of the boxes "i" and "ii" below:)
[i. Counsel states that, upon information and belief, each item of information listed herein was (check one of boxes (a) or (b))
	 (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
	(b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this 1DS.
[A check for the fee set forth in 1.17(p), presently believed to be \$180, is enclosed.
D.	after (A), (B) and (C) above, but before payment of the issue fee: Applicant petitions under 37 C.F.R. 1.97(d) for the consideration of this IDS. Under 37 C.F.R. 1.17(i) a check in the amount of \$180.00 is enclosed. Counsel certifies that, upon information and belief, each item of information listed

2

(check one of the boxes "a" and "b" below:)

herein was

(a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS, or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO/SB/08) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.
(check boxes A, B and/or C and fill in blanks, if appropriate.)
A. Pursuant to the Notice issued by the United States Patent and Trademark Office dated July 11, 2003 waiving the requirements of 37 C.F.R. § 1.98(a)(2)(i), a copy/copies of the United States Patent on PTO/SB08 is/are not being submitted.
B. Document(s) is (are) deemed substantially cumulative to document(s) , and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.
C. Certain documents were previously cited by or submitted to the Office in the following prior applications, which are relied upon under 35 U.S.C. 120:
< <insert &="" date="" filing="" no.="" serial="">></insert>
Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449 and/or PTO/SB/08 from the files of the prior application(s) or a fresh PTO/SB/08 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application.
3. Cite Nos are not in the English language. In accordance with 1.98(c), Applicant states:

	An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language pattent or application, or English-language abstract for claim) is enclosed. The requirement for a concise explanation of the relevance of any foreign language document is satisfied by the attached search report, citation of the documents cited in the search report shall not be construed as an admission that they are or are considered to be, material to patentability of the subject matter claimed herein (See MPEP \$609). A concise explanation of the relevance of document(s) is set forth as follows: [Insert concise explanation of relevance] A concise explanation of the relevance of document(s) can be found on page(s) of the specification.
	A concise explanation of document(s) can be found on the attached sheet.
x 4.	No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 in the preamble to the final rules; 1135 OG 13 at 20).
x 5.	Other information being provided for the examiner's consideration follows:

An International Search Report, dated December 12. 2005, which issued during the prosecution of International Application No. PCT/DK2004/000862 which corresponds to the present application.]

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless other-wise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Early and favorable consideration is earnestly solicited.

5 The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: August 11, 2006

Respectfully submitted, (53, 920) Dianna Goldenson Registration No.: 52,949 DARBY & DARBY P.C. P.O. Box 5257 New York, New York 10150-5257 (212) 527-7700 (212) 527-7701 (Fax) Attorneys/Agents For Applicant

PTC/SB/06a/b (07-06)

Approved for use through 08/30/2006. OMB 0651-0031
U.S. Petent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

to respond to a collection of information unites it contains a valid ONB control number Under the Paperwork Reduction Act of 1995, no persons are required Complete If Known Substitute for form 1449A/B/PTO odication Number 10/596,348-Conf. #5528 INFORMATION DISCLOSURE June 9, 2006 Filing Date STATEMENT BY APPLICANT Pirst Named Inventor Thomas I.f.h. Cremers, Mr. Art Unit (Use as many sheets as necessary) Not Yet Assigned Examiner Name of Attorney Docket Number 05432/0204244-US0

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*	Cha No.1	Document Number Number-Kind Code ² (#Anowe)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear

		FORE	GN PATENT D	OCUMENTS		
Examiner Initals*	Cite No.1	Foreign Patent Document Country Code ² -Number ⁴ -Kind Code ² (Filmown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۲
	BA	EP-0966967	12-29-1999			Н
	BB	WO-99/61027	12-02-1999			Г
	BC	WO-99/20279	04-29-1999			Г
	BD	FP-0978512	02-09-2000			г

"EXAMPLE" Intia if reference considered, whether or not clution is in conformance with IMPEP 50%. Does the through clution if not in conformance and not considered. (Notice copy of the form with most generalized by specific ", "Applicative value statistic enlaptation never large form." "See Nickle Copy of the control projection." "See Nickle Copy of the Copy of th

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, megazine, journal, serial, symposium, catalog, etc.), date, page(e), volume-issue number(e), publisher, dity endor country when published.	т
	CA	SCHLICKER E ET AL "Effects of Inidezolines on nonderenaline release in brain: An investigation into Meri relationship to inidezoline, alphatiga and H3 receptors NEURO-CHEMISTRY INTERNATIONAL. 1997 UNITED KINGDOM, vol. 30, no. 1, 1997, pages 73-83 XP008060001 ISSN: 0197-0197-0197-0197-0197-0197-0197-0197-	
	CB	MCRISSET S ET AL: "Applical neurologica enhance historithes burnous in brain via 5- hydroxyhystamiend Amosphe blockeder" OUDNAL, OF PHRAMODOLOGY AND EVPERMENTAL THERAPEUTICS, vol. 288, no. 2, February 1999 (1999-02), ISSN: 0022- 3966 pages 996-0, PV900059604 iSSN: 0022-3955 page 996, column 1, purgraps 1 page 990, column 2, purgraps 1	
	СС	BONGERS GERALD ET AL. "Role of H3-receptor-mediated signaling in anxiety and cognition in wild-type and Apoel-mice." NEUROPSYCHOPHARMACOLLOGY, vol. 29, no. 3, March 2004 (2004-03), pages 441-469, XP00006995 ISSN: 0980-133X	Ī

"EXAMPLER: Initial if reference considered, whether or not citation is in conformance with MPEP 669. Draw line through citation if not in conformance and not considered. Include copy of this form with need communication to applicant.

"Applicant's unique citation designation number (optional). "Applicant is to place a check mark here if English language Translation is attached

